No "Cert"-ainty On Reverse Settlements: Supreme Court Declines To Take Up Case
This article was originally published in The Pink Sheet Daily
Executive Summary
Lower courts had found Bayer’s agreement with Barr and Hoechst to delay generic Cipro to be lawful; Second Circuit is to rule on the deal.
You may also be interested in...
Reverse Settlements Are Acceptable Under Certain Conditions, DoJ Says
Brand company payments to generic firms to settle infringement suits may not violate antitrust laws if they permit some competition, Department of Justice concludes.
Reverse Settlements Are Acceptable Under Certain Conditions, DoJ Says
Brand company payments to generic firms to settle infringement suits may not violate antitrust laws if they permit some competition, Department of Justice concludes.
FTC's Health Care Reform Plan: Save $12 Billion With Reverse Settlement Ban
The Federal Trade Commission has drawn another arrow in its attempt to shoot down reverse settlements between brand and generic drug companies - offering an estimate of $12 billion in government savings over the next 10 years from ending the practice